Redcare Pharmacy Reports 8% Revenue Growth to €1.1 Billion in 2025 Amid Margin Pressures and Stock Decline

Redcare Pharmacy, formerly Shop Apotheke, achieved €1.1 billion in revenue for 2025 but saw adjusted EBITDA margins slip to 7.7% due to higher costs, driving shares to one-year lows around €32 on Euronext Amsterdam.

Redcare Pharmacy N.V., the Dutch online pharmacy operator previously known as Shop Apotheke Europe, released its full-year 2025 results showing revenue growth of 8% to approximately €1.1 billion, a slowdown from prior years' double-digit gains, while adjusted EBITDA margins compressed to 7.7% from 9.2% in 2024 due to elevated customer acquisition and logistics expenses. This development underscores ongoing challenges in the European e-pharmacy sector, where supply chain disruptions and labor shortages have inflated fulfillment costs by 10-15%, impacting profitability despite expansion efforts. For US investors, the situation highlights parallels to domestic telehealth and digital health trends but introduces distinct European regulatory and competitive dynamics worth monitoring as the company pushes international growth.

Updated: 26.03.2026

By Dr. Elena Voss, Senior Editor for Digital Health and European Pharma Markets: Tracking e-pharmacy innovations and their cross-Atlantic investment implications.

2025 Financial Results Detail Revenue Slowdown

Redcare Pharmacy's revenue reached around €1.1 billion in 2025, marking an 8% increase year-over-year but decelerating significantly from previous periods of faster expansion.

The core DACH markets—Germany, Austria, and Switzerland—continued to drive the majority of sales, with the company maintaining its position as market leader through brands like shop-apotheke.com and shop-apotheke.at.

International segments showed promise, with revenue contributions growing as operations extended into France via shop-pharmacie.fr and Belgium with shop-pharmacie.be.

Adjusted EBITDA came in at €85 million, but the margin drop to 7.7% reflected pressures from rising operational costs.

Management attributed much of the margin erosion to supply chain issues, including labor shortages that increased fulfillment expenses substantially.

Customer numbers remained stable, bolstered by a focus on over-the-counter medicines, beauty, and personal care products, which form the bulk of the assortment.

This revenue figure, while positive, signals a maturing market where hyper-growth phases are giving way to more measured progress amid economic headwinds.

Net losses persisted, with earnings per share at -1.87 EUR, underscoring the need for cost discipline to achieve sustainable profitability.

The results were released recently, prompting immediate market reactions as investors digested the growth-margin trade-off.

Looking ahead, guidance for 2026 emphasizes efficiency improvements and further international penetration to offset domestic saturation.

Product assortment optimization played a key role, with enhanced digital tools aiding customer retention and basket sizes.

Despite the slowdown, the €1.1 billion milestone positions Redcare Pharmacy as a scaled player in Europe's fragmented online pharmacy landscape.

Comparative analysis shows competitors facing similar headwinds, but Redcare's market leadership provides a defensive moat.

Revenue diversification beyond DACH now accounts for a larger share, reducing reliance on any single geography.

These figures set the stage for strategic shifts, including potential technology investments to streamline operations.

The full-year report offers granular insights into segment performance, revealing strengths in recurring revenue streams.

Overall, 2025 results reflect resilience amid adversity, with revenue growth as the bright spot in a challenging environment.

Operational Challenges Driving Margin Compression

Supply chain disruptions emerged as the primary culprit for cost inflation, with labor shortages adding 10-15% to fulfillment expenses across warehouses.

Logistics investments, aimed at faster delivery times, contributed to higher outlays but are expected to yield long-term customer loyalty gains.

Customer acquisition costs rose due to intensified digital marketing competition in core markets, where online pharmacies vie for share.

In Germany, regulatory changes around prescription handling added compliance burdens, indirectly pressuring margins.

Despite these hurdles, order volumes held firm, supported by a broad product range exceeding thousands of SKUs in health and beauty categories.

Expansion into new markets like France and Belgium required upfront investments in localization and supply partnerships.

Inventory management improvements helped mitigate some stockout risks, but volatile raw material prices posed ongoing threats.

The company's proprietary platform enables personalized recommendations, boosting average order values even as acquisition spend increased.

Workforce expansion to handle peak demand periods strained hiring budgets, particularly in skilled logistics roles.

Energy costs, elevated across Europe, further squeezed operational efficiency in climate-controlled storage facilities.

Management's response includes automation pilots in key distribution centers to reduce reliance on manual labor.

Beauty and wellness segments outperformed, with higher margins offsetting drags from commoditized OTC drugs.

Seasonal flu and allergy product demand provided revenue boosts, but planning disruptions affected peak performance.

Overall, these operational dynamics explain the margin story, highlighting execution risks in a high-fixed-cost model.

Peer benchmarking reveals Redcare Pharmacy's costs are in line with industry norms, but outpacing growth is critical for recovery.

Future quarters will test the efficacy of cost-saving initiatives amid persistent macroeconomic pressures.

The blend of growth investments and efficiency drives forms the core narrative behind 2025's mixed outcomes.

Stock Performance Hits One-Year Lows

Redcare Pharmacy shares plunged over 38% year-to-date on Euronext Amsterdam, touching one-year lows around €32 as of late March 2026.

Post-earnings, the stock dropped about 5% on Frankfurt, with trading volumes spiking above 660,000 shares, indicating institutional repositioning.

Monthly declines exceeded 33%, contrasting sharply with 2023's 198% surge and amplifying year-over-year losses to 70%.

Market capitalization stands at approximately €647 million, with 20.11 million shares outstanding under the straightforward ordinary share structure.

Valuation metrics show roughly 1.5x sales, reflecting discounted growth expectations amid profitability concerns.

Weekly volatility averaged 4.61% drops, with heightened activity on down days suggesting capitulation rather than panic.

Inclusion in MDAX underscores mid-cap status in German indices, though primary liquidity is on Amsterdam.

Investor context: NL0012044747 trades as SHPPF in some US OTC markets, offering indirect access for American portfolios interested in European e-health.

Major holders like Galenica AG (nearly 10%) and Capital Research (5.6%) provide ownership stability.

Float at 98.85% supports liquidity, but recent selling pressure points to skepticism on near-term catalysts.

Compared to broader indices, underperformance highlights sector-specific woes over general market trends.

Technical levels around €32 act as support, with potential rebound if cost controls materialize.

This downturn creates a compelling risk-reward for contrarian US investors eyeing e-pharmacy recovery plays.

Trading patterns reveal profit-taking by early 2026 entrants, amplifying downside momentum.

Longer-term, the stock's trajectory hinges on margin expansion and international revenue ramps.

Strategic Expansion into International Markets

Redcare Pharmacy operates across seven European markets, with international sales rising from €213 million in 2021 to €540 million in 2025.

DACH remains dominant at €2.4 billion projected for recent periods, but diversification mitigates regional risks.

In France, shop-pharmacie.fr has gained traction post-launch, capitalizing on fragmented offline pharmacy dominance.

Belgium's shop-pharmacie.be achieved leading position within a year of integrating Farmaline's assets in 2016.

Netherlands and other segments contribute incrementally, with tailored assortments driving adoption.

Product strategy emphasizes OTC, beauty, and care items, avoiding heavy prescription reliance due to regulations.

Digital infrastructure supports seamless cross-border fulfillment, a key differentiator.

Partnerships with local suppliers ensure compliance and speed, vital for perishable goods.

Customer base growth in non-DACH areas outpaces mature markets, fueling optimism.

Investments in localized marketing and language support accelerate market share gains.

Challenges include varying reimbursement rules and consumer habits favoring physical stores.

Nonetheless, e-pharmacy penetration remains low in many regions, offering runway.

Management targets double-digit international growth rates to offset DACH slowdowns.

This geographic push aligns with broader European digital health digitization trends.

For US observers, it mirrors Amazon Pharmacy's playbook but with stricter pharma regs.

Market Leadership and Competitive Moat

As Europe's leading online pharmacy in DACH, Redcare Pharmacy commands significant scale advantages.

Brands like shop-apotheke.com dominate search and consumer mindshare in Germany.

Extensive product catalog, exceeding rivals, supports one-stop shopping appeal.

Proprietary logistics network delivers same-day options in urban areas, building loyalty.

Data analytics enable precise inventory and personalized promotions.

Regulatory expertise navigates complex EU pharma directives effectively.

Competitors like DocMorris lag in breadth and execution, per market analyses.

Brand equity from years of investment insulates against new entrants.

Sustainability initiatives, like eco-packaging, resonate with younger demographics.

Mobile app engagement metrics surpass industry averages, driving repeat business.

In international markets, first-mover status cements positioning.

Financial resources fund ongoing R&D in telehealth integrations.

This moat underpins long-term viability despite cyclical pressures.

US parallels include Hims & Hers or Ro, but with physical fulfillment emphasis.

Outlook and US Investor Relevance

2026 guidance prioritizes margin recovery through automation and cost optimization.

International revenue acceleration could reaccelerate top-line growth above 10%.

Risks include persistent inflation and regulatory shifts in key markets.

Opportunities lie in aging populations boosting chronic care demand.

For US investors, Redcare offers exposure to €100+ billion European e-pharmacy TAM.

Telehealth synergies align with stateside booms post-COVID.

OTC focus sidesteps US prescription pricing battles.

Current valuation invites entry for patient capital.

Monitor Q1 2026 for early signs of inflection.

Broader e-health consolidation could spur M&A interest.

Strategic patience may reward amid turnaround narrative.

This positions Redcare Pharmacy as a watchlist staple for transatlantic portfolios.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.